Targeted degradation of KRAS by an engineered ubiquitin ligase suppresses pancreatic cancer cell growth in vitro and in vivo.

@article{Ma2013TargetedDO,
  title={Targeted degradation of KRAS by an engineered ubiquitin ligase suppresses pancreatic cancer cell growth in vitro and in vivo.},
  author={Yihui Ma and Yumei Gu and Qiang Zhang and Yongqing Han and Shuangni Yu and Zhaohui Lu and Jie Chen},
  journal={Molecular cancer therapeutics},
  year={2013},
  volume={12 3},
  pages={286-94}
}
KRAS is an attractive pancreatic ductal adenocarcinoma (PDAC) therapeutic target. E3 ligase is thought to be the component of the ubiquitin conjugation system that is directly responsible for substrate recognition. In this study, an engineered E3 ubiquitin ligase (RC-U) was generated to target the KRAS oncoprotein for ubiquitination and degradation. The engineered E3 ubiquitin ligases (RC-U) were constructed (pRC-U and lentivirus-expressing RC-U). After transfecting the pRC-U plasmid into human… CONTINUE READING